Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Literature DB >> 22288400

Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Masashi Kitazawa¹, Rodrigo Medeiros, Frank M Laferla.

Abstract

Alzheimer disease (AD) is the leading cause of dementia among elderly. Currently, no effective treatment is available for AD. Analysis of transgenic mouse models of AD has facilitated our understanding of disease mechanisms and provided valuable tools for evaluating potential therapeutic strategies. In this review, we will discuss the strengths and weaknesses of current mouse models of AD and the contribution towards understanding the pathological mechanisms and developing effective therapies.

Entities: Disease Species

Mesh：

Year: 2012 PMID： 22288400 PMCID： PMC4437619 DOI： 10.2174/138161212799315786

Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116

229 in total

Review 1. Caspase-mediated degeneration in Alzheimer's disease.

Authors: David H Cribbs; Wayne W Poon; Robert A Rissman; Mathew Blurton-Jones
Journal: Am J Pathol Date: 2004-08 Impact factor: 4.307

2. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.

Authors: M C Chartier-Harlin; F Crawford; H Houlden; A Warren; D Hughes; L Fidani; A Goate; M Rossor; P Roques; J Hardy
Journal: Nature Date: 1991-10-31 Impact factor: 49.962

Review 3. Alzheimer's disease.

Authors: Henry W Querfurth; Frank M LaFerla
Journal: N Engl J Med Date: 2010-01-28 Impact factor: 91.245

4. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.

Authors: Naruhiko Sahara; Jada Lewis; Michael DeTure; Eileen McGowan; Dennis W Dickson; Mike Hutton; Shu-Hui Yen
Journal: J Neurochem Date: 2002-12 Impact factor: 5.372

Review 5. Management and design of the maintenance of SAM mouse strains: an animal model for accelerated senescence and age-associated disorders.

Authors: M Hosokawa; T Abe; K Higuchi; K Shimakawa; Y Omori; T Matsushita; K Kogishi; E Deguchi; Y Kishimoto; K Yasuoka; T Takeda
Journal: Exp Gerontol Date: 1997 Jan-Apr Impact factor: 4.032

6. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors: Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal: Am J Pathol Date: 2007-08-23 Impact factor: 4.307

7. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors: Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal: Lancet Neurol Date: 2007-11-05 Impact factor: 44.182

8. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

Authors: Sethu Sankaranarayanan; Eric A Price; Guoxin Wu; Ming-Chih Crouthamel; Xiao-Ping Shi; Katherine Tugusheva; Keala X Tyler; Jason Kahana; Joan Ellis; Lixia Jin; Thomas Steele; Shawn Stachel; Craig Coburn; Adam J Simon
Journal: J Pharmacol Exp Ther Date: 2007-12-21 Impact factor: 4.030

9. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.

Authors: Gen He; Wenjie Luo; Peng Li; Christine Remmers; William J Netzer; Joseph Hendrick; Karima Bettayeb; Marc Flajolet; Fred Gorelick; Lawrence P Wennogle; Paul Greengard
Journal: Nature Date: 2010-09-02 Impact factor: 49.962

10. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

Authors: Jun Maeda; Bin Ji; Toshiaki Irie; Takami Tomiyama; Masahiro Maruyama; Takashi Okauchi; Matthias Staufenbiel; Nobuhisa Iwata; Maiko Ono; Takaomi C Saido; Kazutoshi Suzuki; Hiroshi Mori; Makoto Higuchi; Tetsuya Suhara
Journal: J Neurosci Date: 2007-10-10 Impact factor: 6.167

46 in total

Review 1. The case for rejecting the amyloid cascade hypothesis.

Authors: Karl Herrup
Journal: Nat Neurosci Date: 2015-06 Impact factor: 24.884

2. Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons.

Authors: Michael S Fernandopulle; Ryan Prestil; Christopher Grunseich; Chao Wang; Li Gan; Michael E Ward
Journal: Curr Protoc Cell Biol Date: 2018-05-18

Review 3. Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.

Authors: Chinthalapally V Rao; Mudassir Farooqui; Adam S Asch; Hiroshi Y Yamada
Journal: Cell Cycle Date: 2018-09-20 Impact factor: 4.534

4. Upregulation of miR-181 decreases c-Fos and SIRT-1 in the hippocampus of 3xTg-AD mice.

Authors: Carlos J Rodriguez-Ortiz; David Baglietto-Vargas; Hilda Martinez-Coria; Frank M LaFerla; Masashi Kitazawa
Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472

5. Alzheimer's disease: A clinical perspective and future nonhuman primate research opportunities.

Authors: Rafi U Haque; Allan I Levey
Journal: Proc Natl Acad Sci U S A Date: 2019-12-23 Impact factor: 11.205

6. Aβ Plaques.

Authors: Lary C Walker
Journal: Free Neuropathol Date: 2020-10-30

Review 7. Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.

Authors: Aida Attar; Gal Bitan
Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116